InRAD receives funding from Novo Nordisk and Eli Lilly

InRAD is delighted to announce  €1.5m* funding support from Eli Lilly and Novo Nordisk to advance efforts.

We are excited  to announce that InRAD has raised an additional €1,469,974.00 of funding support from Novo Nordisk and Lilly UK.

*Exact amounts:

Eli Lilly  (collaborative research agreement)

€1,440,000

Novo Nordisk (grant  agreement)

€30,000

This financing will allow us to start the next phase of building the registry platform, participate in scientific engagement activities including presence atkey educational conferences, support the development of the minimum dataset manuscript, and fund various workstream projects.

We thank our partners supporting us and joining us on this journey to advance our collective understanding of Alzheimer’s Disease and other dementias.

For more information on how you can get involved, please contact us on info@InRADnetwork.org 

About InRAD

An international, practice-based registry for Alzheimer’s Disease and other dementias. Providing collaborative database tools and research capabilities to support patient care and advance knowledge through epidemiological and outcomes studies.

‍

‍

‍